Immutep announces successful meeting with FDA on phase III design in non-small cell lung cancer
- Immutep received positive feedback from the FDA on the TACTI-004 Phase III trial design for efti in combination with KEYTRUDA and standard chemotherapy.
- The trial will enrol approximately 750 patients with first-line metastatic non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.
- The trial design is based on positive efficacy and safety data from the TACTI-002 Phase II and INSIGHT-003 trials.
- The dual primary endpoints will be progression-free survival and overall survival, with a pre-planned interim analysis.
Read more
MAIA Biotechnology announces new updates from Phase 2 trial of novel cancer treatment agent
- MAIA Biotechnology reports positive updates from its Phase 2 trial, THIO-101, for advanced non-small cell lung cancer (NSCLC).
- The trial involves THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo) in patients who failed two or more standard-of-care therapies.
- 6 patients have remained on treatment for at least 12 months, showing lower toxicity and ongoing benefits.
- THIO-101 is a multicenter, open-label, dose-finding Phase 2 trial designed to evaluate the safety, tolerability, and clinical efficacy of THIO followed by cemiplimab.
Read more
MitoCareX confirms potential significant role of its drug target in non-small cell lung cancer
- MitoCareX Bio, a venture of SciSparc Ltd., validated the significant involvement of its target SLC25 carrier protein in NSCLC cells.
- The discovery was demonstrated using genetic manipulations and 3D spheroid systems, mimicking human solid tumors.
- NSCLC accounts for 80%-85% of all lung cancer cases globally, with the market projected to reach $59.77 billion by 2030.
- MitoCareX is developing a predictive AI model to uncover novel anti-cancer small molecule scaffolds targeting the SLC25 protein.
Read more
TCBP announces dosing of 6th patient in ACHIEVE study in patients with acute myeloid leukemia
- The sixth patient in the ACHIEVE UK clinical trial was treated with a higher dose of TCB-008.
- The ACHIEVE study is an open-label, phase II trial evaluating TCB-008 in patients with AML or MDS/AML.
- Cohort A includes relapsed/refractory patients, while Cohort B includes patients in remission with residual disease.
- The trial allows for up to 24 patients in each cohort, with potential advancement to a Phase III Pivotal Trial.
Read more
Precision Biologics granted patent for NEO-201 targeting Treg cells
- Precision Biologics received a patent from the USPTO for its monoclonal antibody, NEO-201, on July 16, 2024.
- NEO-201 targets regulatory T cells (Treg cells) and granulocytic myeloid-derived suppressor cells (gMDSCs), enhancing cancer immunotherapy efficacy.
- The patent covers methods for isolating and detecting Treg cells and using NEO-201 in combination therapies.
- Ongoing Phase 2 trial is evaluating NEO-201 with pembrolizumab (Keytruda) in patients with solid tumors resistant to prior checkpoint inhibitors.
Read more
TransCode Therapeutics announces pricing of public offering
- TransCode Therapeutics priced a public offering of 10,000,000 shares at $0.30 per share.
- The offering is expected to generate gross proceeds of $3,000,000 before expenses.
- Proceeds will be used for product development, including clinical trials for TTX-MC138, and general corporate purposes.
- The offering is expected to close on July 24, 2024, subject to customary conditions.
Read more
Frontier Medicines announces milestone payment in AbbVie partnership
- Frontier Medicines advanced lead candidates targeting a key transcription factor for cancer cell survival.
- This progress triggered a milestone payment from AbbVie.
- The partnership aims to develop small molecule therapeutics against difficult-to-drug protein targets.
- Frontier is eligible for milestone payments exceeding $1 billion and royalties on commercialized products.
Read more
